R Stock Recent News

Toronto, Ontario--(Newsfile Corp. - June 27, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase ®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses, is pleased to announce that the Company proposes to extend the expiry date of 4,800,000 share purchase warrants ("Warrants") expiring June 30th, 2025 to June 30th, 2028. The Warrants were issued on June 30th, 2023, pursuant to a private placement involving the issuance of 4,800,000 units of the Company.

MIAMI--(BUSINESS WIRE)-- #RyderEverbetter--Ryder System, Inc. (NYSE: R) expects to issue its second quarter 2025 results at approximately 7:00 a.m. Eastern Time on Thursday, July 24, 2025. The company will also host a conference call at 11 a.m. Eastern Time on the same day. The call will be webcast live and a replay will be available. Details for the call include: When: Thursday, July 24, 2025 from 11:00 a.m. to 12:00 p.m. Eastern Time   How: Live webcast: Ryder System Second Quarter 2025 Earnings Release Confere.

Amneal holds exclusive U.S. commercialization rights; BLA filing expected in Q4 2025 Poised to be among the first wave of biosimilars in the $3.9 billion U.S. omalizumab market and an important growth driver for Amneal BRIDGEWATER, N.J., June 25, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today highlighted positive topline results from a confirmatory clinical efficacy and safety clinical trial evaluating ADL-018, a proposed biosimilar to XOLAIR® (omalizumab), developed by Kashiv BioSciences, LLC.

MIAMI--(BUSINESS WIRE)--As competition for top talent increases across the transportation and logistics industry, Ryder System, Inc. (NYSE: R) continues to stand out as an employer of choice committed to fostering a supportive and innovative workplace where our employees can thrive. In recognition of these efforts, Newsweek has once again named Ryder to its America's Greatest Workplaces list for 2025. This marks Ryder's second consecutive year earning this designation, with the company receivin.

Intellectual Property Portfolio grows to 221 Patents and 140 Trademarks ANN ARBOR, MI / ACCESS Newswire / June 24, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the issuance of a new patent related to its TRUVIEW microscope and provided an update on the Company's current intellectual property portfolio. The U.S. Patent related to the TRUVIEW microscope, manufactured, sold and distributed by Zomedica, was U.S. Patent No.

CENTENNIAL, CO / ACCESS Newswire / June 23, 2025 / NioCorp Developments Ltd. ("NioCorp" or the "Company") (NASDAQ:NB) is pleased to announce that it will be added as a member of the broad-market Russell 3000Index, effective after the U.S. market opens on June 30, 2025, as part of the 2025 Russell indexes reconstitution.

MIAMI--(BUSINESS WIRE)-- #RyderEverbetter--Ryder announces “Driver of the Year” awards, celebrating three professional truck drivers who exemplify safety, service, and leadership.

Next-Generation Diagnostic Platform Takes Center Stage in Monthly Series Showcasing Innovation in Veterinary Care ANN ARBOR, MI / ACCESS Newswire / June 19, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic device products for equine and companion animals, is pleased to announce the next installment of its Fourth Friday at Four webinar series, scheduled for Friday, June 27 at 4:00 PM ET featuring the TRUFORMA diagnostic platform. This month's feature will dive deep into the TRUFORMA diagnostic platform, Zomedica's game-changing in-clinic system that is setting new standards in point-of-care veterinary diagnostics.

Toronto, Ontario--(Newsfile Corp. - June 17, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses is pleased to announce that it has successfully closed a non-brokered private placement offering ("Offering") of units ("Units"). On closing, the Corporation issued an aggregate of 2,855,000 Units at a price of $CAN 0.20 per Unit for aggregate gross proceeds of approximately $CAN 571,000.

~ Andrew J. Trontis, MD from Progressive Spine and Orthopaedics, (Englewood, NJ) Completes Initial Case Series ~ LOS GATOS, CA / ACCESS Newswire / June 12, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today announced the completion of an initial case series utilizing the Catamaran® SI Joint Fusion System (the "Catamaran") to immobilize & stabilize the SI Joint providing added support at the base of a lumbar or thoracolumbar fusion.